Summary & Overview
HCPCS Level II J0139: Injection of Adalimumab, 1 mg
HCPCS Level II code J0139 identifies a per-milligram billing unit for adalimumab injection (1 mg). This code matters nationally because adalimumab is a widely used biologic for multiple inflammatory and autoimmune conditions, and per-unit billing affects procurement, reimbursement pathway management, and billing accuracy across outpatient and clinic settings. The analysis covers major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn how J0139 is used in clinical and billing workflows, what typical sites of service are for adalimumab administration, and which payers are commonly involved. The publication provides practical benchmarks for payers and providers, summarizes relevant policy and coverage considerations, and situates the code in clinical context for conditions commonly treated with adalimumab. Data not available in the input is noted where applicable, and the content focuses on national implications rather than state-specific rules.
Billing Code Overview
HCPCS Level II code J0139 represents injection, adalimumab, 1 mg, a biologic therapeutic agent administered by injection. The service type for this code is drug administration / injectable medication, and the typical site of service is outpatient infusion or injection settings such as physician offices, hospital outpatient departments, ambulatory infusion centers, and clinic-based administration.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a chronic inflammatory condition such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa, or Crohn disease who requires subcutaneous biologic therapy with adalimumab. The patient presents to an outpatient infusion clinic, specialty pharmacy clinic, or a physician office for administration counseling, medication dispensing verification, and observation for adverse reaction after self-injection training or clinic-administered injection. The clinical workflow includes medication order verification, confirmation of diagnosis and prior authorization status, review of allergies and infection risk (including screening for active infections and tuberculosis where indicated), documentation of lot number and expiration, preparation of the dose (calculated in milligrams), administration of the subcutaneous injection, monitoring for 15–30 minutes for immediate hypersensitivity, and documentation of the service and medication details in the medical record and the billing system using the HCPCS code J0139 billed per milligram of adalimumab supplied.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (default) | Use when no special circumstances apply; standard billing for the medication. |
22 | Increased procedural services | Use when significantly greater work is required for drug preparation or administration beyond typical complexity (rare for standard subcutaneous injection).